Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782687 · ClinicalTrials.gov registry record · Phase 2
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma, sponsored by US Oncology Research.
- Active
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 10
- Study locations
NCT04782687 is a Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma that is active but no longer recruiting, run by US Oncology Research. The registered enrollment target is 73 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT04782687, a Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma, is active but no longer recruiting, sponsored by US Oncology Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Dexamethasone Oral
Study Locations (10)
Texas
- Texas Oncology, P.A. - Austin
- Texas Oncology, P.A. - Fort Worth
- Texas Oncology, P.A. - San Antonio
- Texas Oncology, P.A. - Tyler
Arizona
- Arizona Oncology Associates, PC - HOPE - Tucson
Colorado
- Rocky Mountain Cancer Centers - Denver
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
New York
- New York Oncology Hematology, P.C. - Albany
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
Virginia
- Virginia Cancer Specialists, PC - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04782687
The ClinicalTrials.gov registry entry for NCT04782687 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Selinexor is the first listed.
NCT04782687 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04782687 about?
NCT04782687 is a clinical study titled "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma". This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior t...
What is the current status of trial NCT04782687?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2021-09-10. Estimated completion is 2026-05-31.
What conditions does trial NCT04782687 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Myeloma Multiple, Myeloma, Plasma Cell, Kahler Disease.
What interventions are being tested in trial NCT04782687?
The interventions under investigation include: Selinexor (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Dexamethasone Oral (DRUG).
Who is sponsoring clinical trial NCT04782687?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782687 being conducted?
This trial has 10 study locations across Arizona, Colorado, Maryland, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.